Literature DB >> 30905717

Efficacy of Enteric-Release Oral Budesonide in Treatment of Acute Reactions to Gluten in Patients With Celiac Disease.

Amelie Therrien1, Jocelyn A Silvester2, Daniel A Leffler3, Ciaran P Kelly4.   

Abstract

Celiac disease (CeD) is a common gluten-responsive T cell-mediated enteropathy. The only current treatment is gluten avoidance; however, even when attempting to adhere to a gluten-free diet (GFD), symptomatic gluten exposures are frequent.1.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30905717      PMCID： PMC6754800          DOI： 10.1016/j.cgh.2019.03.029

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  8 in total

Review 1.  Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Maria Teresa Busceti; Francesco Fabiano; Rosa Terracciano; Maria Gabriella Matera; Rosario Maselli
Journal:  Pulm Pharmacol Ther       Date:  2016-07-02       Impact factor: 3.410

2.  Challenge with gliadin induces eosinophil and mast cell activation in the jejunum of patients with celiac disease.

Authors:  B Lavö; L Knutson; L Lööf; B Odlind; P Venge; R Hällgren
Journal:  Am J Med       Date:  1989-12       Impact factor: 4.965

3.  Open-Capsule Budesonide for Refractory Celiac Disease.

Authors:  Saurabh S Mukewar; Ayush Sharma; Alberto Rubio-Tapia; Tsung-Teh Wu; Bana Jabri; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2017-03-21       Impact factor: 10.864

4.  Celiac crisis is a rare but serious complication of celiac disease in adults.

Authors:  Shailaja Jamma; Alberto Rubio-Tapia; Ciaran P Kelly; Joseph Murray; Robert Najarian; Sunil Sheth; Detlef Schuppan; Melinda Dennis; Daniel A Leffler
Journal:  Clin Gastroenterol Hepatol       Date:  2010-04-24       Impact factor: 11.382

5.  Symptomatic suspected gluten exposure is common among patients with coeliac disease on a gluten-free diet.

Authors:  J A Silvester; L A Graff; L Rigaux; J R Walker; D R Duerksen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

6.  Mast cells are associated with the onset and progression of celiac disease.

Authors:  Barbara Frossi; Claudio Tripodo; Carla Guarnotta; Antonio Carroccio; Marco De Carli; Stefano De Carli; Marco Marino; Antonino Calabrò; Carlo E Pucillo
Journal:  J Allergy Clin Immunol       Date:  2016-09-13       Impact factor: 10.793

7.  Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo/in vitro pilot study.

Authors:  C Ciacci; L Maiuri; I Russo; R Tortora; C Bucci; C Cappello; A Santonicola; A Luciani; V Passananti; P Iovino
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-05-19       Impact factor: 2.557

8.  Budesonide in the treatment of refractory celiac disease.

Authors:  Pardeep Brar; Susie Lee; Suzanne Lewis; Ikenna Egbuna; Govind Bhagat; Peter H R Green
Journal:  Am J Gastroenterol       Date:  2007-06-20       Impact factor: 10.864
  8 in total
  1 in total

Review 1.  Celiac Disease: Extraintestinal Manifestations and Associated Conditions.

Authors:  Amelie Therrien; Ciaran P Kelly; Jocelyn A Silvester
Journal:  J Clin Gastroenterol       Date:  2020-01       Impact factor: 3.174
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.